Medical scientists have recently discovered that the COVID-19 viral load in infected patients could be substantially reduced with the aid of Nitric oxide nasal spray (NONS), a self-administered medication formulated by a Vancouver-based biotech firm, SaNOtize.
Reports reveal that some institutions which include; SaNOtize, Ashford and St Peter’s Hospitals NHS Foundation Trust, and Berkshire and Surrey Pathology Services in the UK, have confirmed the recent discovery, stating that although the results have just passed through their second phase experiments, it has been demonstrated that the nasal spray can effectively and efficiently represent an antiviral therapy that could deter the transmission of COVID-19, reduce its length for those who are already infected by it and also reduce the harshness too.
Also, the treatment is said to kill the virus in the upper airways, preventing it from incubating and making its way to the lungs which oftentimes is where it becomes critical and fatal.
According to medical experts in SaNOtize, explain Ed the recent discovery, they started that; “A randomized, double-blind, placebo-controlled phase two trial that evaluated 79 confirmed cases of COVID-19 — considerably lessened the degree of SARS-CoV-2, involving patients with high viral loads.”
Medical observations from experiments conducted so far indicated that patients who were administered the SaNOtize spray were seen to have experienced an average viral load reduction of 1.362 in the first 24 hours, which corresponds with a decline of around 95 percent, and within 72 hours the viral load declined by more than 99 percent.
It is significant to note also, that most of the patients for whom these tests were conducted, were those infected with the UK variant, which is considered a variant of concern. Moreover, it was noticed that no negative health incidents were documented in the UK trial and in the 7,000 self-administered treatments given in the Canadian clinical trials.
Speaking on the recent development, a principal investigator and virologist Stephen Winchester, disclosed that the treatment will rapidly curtail the spread of the virus.
In his words; “I expect this to be a major advance in the global battle against the devastating human impacts of the COVID-19 pandemic.”
“This simple portable nasal spray could be highly effective in the treatment of COVID-19 and reducing onward transmission.
“Our trial included patients with a variant of concern and high viral loads yet still demonstrated significant reductions in the levels of SARS-CoV-2, which could be critical in supporting vaccines, preventing future outbreaks, and safely reopening economies. Simply stated, I think this could be revolutionary.”
Furthermore, Gilly Regev, chief executive officer (CEO) and co-founder of SaNOtize, confirmed in a statement that urgent endorsement of the medication will promote unexpected recovery to normalcy.
“Now that NONS has been demonstrated to be safe and effective in clinical trials, we must move with urgency to get it into the hands of the public where it can help bring an end to the pandemic, accelerate a return to normalcy, and prevent future outbreaks of COVID-19 and its variants,”